



(51) International Patent Classification:
C07K 14/725 (2006.01) A61K 35/17 (2015.01)

(21) International Application Number:
PCT/GB2020/050120

(22) International Filing Date:
20 January 2020 (20.01.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1900858.0 22 January 2019 (22.01.2019) GB
62/951,770 20 December 2019 (20.12.2019) US

(71) Applicant: IMMETACYTE LIMITED [GB/GB]; 48
Grafton Street, Manchester Greater Manchester M13 9XX
(GB).

(72) Inventors: BRIDGEMAN, John; Immetacyte Limited,
48 Grafton Street, Manchester Greater Manchester M13
9XX (GB). HAWKINS, Robert; Immetacyte Limited, 48
Grafton Street, Manchester Greater Manchester M13 9XX
(GB).

(74) Agent: APPLEBYARD LEES IP LLP; 15 Clare Road, Hal-
ifax, Yorkshire, HX1 2HY (GB).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: RECEPTORS PROVIDING TARGETED COSTIMULATION FOR ADOPTIVE CELL THERAPY




Fig. 1

(57) Abstract: The present invention relates to a cell comprising a chimeric costimulatory antigen receptor (CoStAR) useful in adoptive cell therapy (ACT). The CoStAR can act as a modulator of cellular activity enhancing responses to defined antigens. The present invention also provides CoStAR proteins, nucleic acids encoding the CoStAR and therapeutic uses thereof.

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*